Dear Editor, we read the publication on “The synergistic effect between adult weight changes and CYP24A1 polymorphisms is associated with pre- and postmenopausal breast cancer (BC) risk” with great interest . Cao et al. noted that “Significant interactions of weight change with CYP24A1 polymorphisms suggest CYP24A1 as a potential link between weight change and BC risk .” Indeed, there are several factors that are associated with BC risk. Regarding the effect of CYP24A1 polymorphisms, single mutations were studied by Cao et al. The pathogenesis of studied CYP24A1 polymorphisms is molecular change due to mutation. Based on the standard molecular calculation technique, as mentioned in previous publications , the molecular weight changes in C/T and A/G variants are equal to + 15 (from 111.1 to 126.1) and + 16 ( from 135.1 to 151.1) g/Mol, respectively. Nevertheless, there are also other possible genetic polymorphisms that are related to BC risk. The examples are ACVB1 and AGER polymorphisms [3, 4]. The effects of other additional confounding factors should be assessed in future studies.
Cao S, Wei F, Zhou J, Zhu Z, Li W, Wu M (2019) The synergistic effect between adult weight changes and CYP24A1 polymorphisms is associated with pre- and postmenopausal breast cancer risk. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-019-05484-6
Joob S, Guran M (2019) PRDM1 rs1010273 polymorphism and survival of patients with hepatitis B virus-related hepatocellular carcinoma. Adv Lab Med Int 9:31–32
Liu H, Wei Z, Shi K, Zhang Y (2019) Association between ABCB1 G2677T/A Polymorphism and Breast Cancer Risk: A Meta-Analysis. Crit Rev Eukaryot Gene Expr 29(3):243–249
Ghafouri-Fard S, Noroozi R, Musavi M, Taheri M (2019) Association analysis between genomic variants within advanced glycation end product specific receptor (AGER) gene and risk of breast cancer in Iranian women. Heliyon 5(10):e02542
Conflict of interest
All authors declare that they have no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
This is not a study on human or animal subject and requires no informed consent.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Joob, B., Wiwanitkit, V. CYP24A1 polymorphisms and breast cancer risk. Breast Cancer Res Treat (2020). https://doi.org/10.1007/s10549-020-05553-1